CAR-T Cell Therapy and Gut Microbiota Modulation in MS
Research suggests that CAR-T cells can effectively target and eliminate B cells in multiple sclerosis (MS). Additionally, the gut microbiota is found to play a significant role in immune system balance related to MS.
- Most relevant to
- Neurologist, Immunologist
Why it matters
Understanding how CAR-T therapy and gut microbiota interact offers insight into potential new therapeutic strategies for MS, though efficacy in human patients remains unproven.
What this does not prove
The findings do not demonstrate clinical efficacy for CAR-T therapy in MS patients, nor do they clarify how gut microbiota modulation influences MS symptoms or progression.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-19
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceCAR-T Cell Therapy and Gut Microbiota in MS ↗
Supporting passages (4)
interventionTitle: CAR-T Cell Therapy and Gut Microbiota Modulation in Multiple Sclerosis: Emerging Therapeutic Strategies and Current Limitations.
findingsRecent discoveries have also revealed an important role for the gut microbiota in maintaining immune homeostasis.
publication datePublication date: 2026-09-19
limitationsTitle: CAR-T Cell Therapy and Gut Microbiota Modulation in Multiple Sclerosis: Emerging Therapeutic Strategies and Current Limitations.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.